Previous studies examining the targeting of SK2 in myeloma employed ABC294640 [11], a SK2 inhibitor that has been recently shown to display off target effects by more potently inhibiting dihydroceramide desaturase [15, 16]. Here, SPHK2 is linked to plasma cell myeloma.